Lacktman Comments on Confusion Over DEA’s Telemedicine Rulemaking
April 22, 2019
Politico
Partner Nate Lacktman was quoted in a Politico article, “HHS extends interoperability comment window,” about lingering confusion over an expected Drug Enforcement Administration rule that is supposed to clarify when doctors can register to prescribe controlled substances via telemedicine.
Lacktman said it is not clear what will be in the rule, which is expected to come out in October. If the rule isn’t specific enough or if it restricts prescribing to certain specialties or substances, clinicians might not feel comfortable prescribing virtually, he said.
Lacktman said it is not clear what will be in the rule, which is expected to come out in October. If the rule isn’t specific enough or if it restricts prescribing to certain specialties or substances, clinicians might not feel comfortable prescribing virtually, he said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."